Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2008 3
2010 1
2013 2
2015 3
2018 3
2019 5
2020 6
2021 4
2022 12
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Albain KS, et al. Among authors: lu j. Clin Cancer Res. 2024 Feb 16;30(4):729-740. doi: 10.1158/1078-0432.CCR-22-2256. Clin Cancer Res. 2024. PMID: 38109213 Clinical Trial.
Charles David Allis (1951-2023).
Chi P, Lewis PW, Lu C, Lu J, Ruthenburg AJ, Sabari BR, Shechter D, Wan L, Wang GG. Chi P, et al. Among authors: lu j. Nat Genet. 2023 Apr;55(4):522-523. doi: 10.1038/s41588-023-01331-z. Nat Genet. 2023. PMID: 36849658 No abstract available.
Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions.
Jayachandran P, Battaglin F, Strelez C, Lenz A, Algaze S, Soni S, Lo JH, Yang Y, Millstein J, Zhang W, Shih JC, Lu J, Mumenthaler SM, Spicer D, Neman J, Roussos Torres ET, Lenz HJ. Jayachandran P, et al. Among authors: lu j. Oncogene. 2023 Feb;42(9):627-637. doi: 10.1038/s41388-022-02584-4. Epub 2023 Jan 18. Oncogene. 2023. PMID: 36650218 Free PMC article. Review.
Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer.
Setayesh SM, Hart O, Naghdloo A, Higa N, Nieva J, Lu J, Hwang S, Wilkinson K, Kidd M, Anderson A, Velasco CR, Kolatkar A, Matsumoto N, Nevarez R, Hicks JB, Mason J, Shishido SN, Kuhn P. Setayesh SM, et al. Among authors: lu j. NPJ Breast Cancer. 2022 Sep 27;8(1):112. doi: 10.1038/s41523-022-00480-4. NPJ Breast Cancer. 2022. PMID: 36167819 Free PMC article.
Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients.
Culver JO, Freiberg Y, Ricker C, Comeaux JG, Chang EY, Banerjee V, Sturgeon D, Solomon I, Kagey J, Dobre MG, Carey J, Carr A, Cho S, Lu J, Kang IM, Patel K, Terando A, Ye JC, Li M, Lerman C, Spicer D, Nelson M. Culver JO, et al. Among authors: lu j. Ann Surg Oncol. 2023 Feb;30(2):1017-1025. doi: 10.1245/s10434-022-12595-w. Epub 2022 Sep 26. Ann Surg Oncol. 2023. PMID: 36161375 Free PMC article.
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA. Osdoit M, et al. Among authors: lu j. JAMA Surg. 2022 Nov 1;157(11):1034-1041. doi: 10.1001/jamasurg.2022.4118. JAMA Surg. 2022. PMID: 36069821 Free PMC article. Clinical Trial.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Bidard FC, et al. Among authors: lu j. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. J Clin Oncol. 2022. PMID: 35584336 Free PMC article. Clinical Trial.
41 results